Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care Settings

OBJECTIVES: Adults aged ≥60 years and adults with certain health conditions are at increased risk for severe respiratory syncytial virus (RSV) disease, which can have a substantial clinical burden. Residents in long-term care settings often have multiple risk factors, including age ≥60 years, underlying health conditions, and/or frailty, compounding risk for severe RSV disease. This study evaluated the public health impact of adjuvanted RSV prefusion F3 (RSVPreF3) vaccination on averted RSV disease burden. DESIGN: Public health impact analysis using a static, multicohort Markov model. SETTING AND PARTICIPANTS: United States (US) adults aged ≥60 years residing in long-term care settings. METHODS: Adjuvanted RSVPreF3 vaccination vs no vaccination was simulated over 5 years using real-world RSV vaccination uptake data. Other model inputs have been previously validated and reported. This analysis estimated avoided RSV-related health outcomes due to vaccination, as well as the number needed to vaccinate (NNV) to avoid RSV-related outcomes. RESULTS: Among the modeled 2,113,600 US adults aged ≥60 years residing in long-term care settings, 378,656 were simulated to receive 1 dose of adjuvanted RSVPreF3. RSV vaccination resulted in 33,989 fewer RSV cases, including 7688 fewer RSV-upper respiratory tract disease cases and 26,302 fewer RSV-lower respiratory tract disease cases (RSV-LRTD). Avoided healthcare resource use included 19,639 fewer outpatient visits, 1556 fewer emergency department visits, and 11,634 fewer hospitalizations. RSV-related deaths declined by 1355 over 5 years, alongside 7221 and 6043 fewer discounted life years and quality-adjusted life years lost, respectively. To avoid 1 RSV-LRTD case, the estimated NNV was 14 individuals. CONCLUSIONS AND IMPLICATIONS: Adjuvanted RSVPreF3 vaccination avoided a substantial number of negative health outcomes among US adults aged ≥60 years residing in long-term care settings, providing evidence of its impact as a prevention strategy. Future efforts are needed to ensure that long-term care residents have access to RSV vaccination.